Namhee Lim

I focus on providing support to biotech businesses on the strategic and commercial aspects of early asset development. In order to maximize asset value, it is critical for biotech businesses to establish a clear commercial strategy for their assets from early in the development process, starting during Ph2. Key topics include:

❖ Ensuring that clinical plans are linked to a clear commercial strategy: a data package which facilitates a successful launch and rapid uptake will add substantial value to an asset regardless of whether the goal is to launch or sell it – this requires an early input to pivotal clinical plans.
❖ Market assessment by key markets and target segments: establish value potential, differentiation, pricing strategy, routes to market, key influencers, product presentation, etc. to ensure that strategy is based on rigorous commercial analysis.
❖ Launch preparation, planning and execution: deliver a comprehensive launch plan, including go to market strategy and a phased commercial capability building plan, and implement it in the market to ensure early adoption and rapid uptake.
❖ Strengthen investor prospectus: investors are more likely to fund a project if the management team can show they have a clear strategic vision for the commercialisation of the asset and are committed to getting the data to deliver that vision.
❖ Strengthen negotiating position for out-licence: ensure that commercial value is accurately assessed and rigorously supported in due diligence exercises with acquiring businesses.

I have over 20 years commercial experience in pharmaceuticals and biologicals, with in-depth knowledge of global markets including Asia Pacific and emerging markets, as well as US and EU. This includes recent responsibility for leading the commercial input to major assets in development. I have worked in Korea, Singapore, Switzerland, Belgium and, since 2006, the UK.